The story of pyrimethamine (Daraprim) has been splashed across the news. Turing Pharmaceuticals , run by a former hedge fund manager, acquires the drug, which treats a life-threatening parasitic infection, and raises the price from $13.50 to $750. The
Read More...
Read the complete post at http://healthaffairs.org/blog/2015/10/21/the-daraprim-price-hike-and-a-role-for-antitrust/
Posted
Oct 21 2015, 07:37 AM
by
Health Affairs Blog